H.L.A. Janssen

58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION

Hendrik W. Reesink, H.L.A. Janssen, Stefan Zeuzem et al. · Journal of Hepatology · 2012 · 61 citations

Placebo-controlled Safety, Viral Hepatitis, Immunodeficiencies +8

86 SAFETY AND ANTIVIRAL ACTIVITY OF SCH 900518 ADMINISTERED AS MONOTHERAPY AND IN COMBINATION WITH PEGINTERFERON ALFA-2B TO NAIVE AND TREATMENT-EXPERIENCED HCV-1 INFECTED PATIENTS

H. W. Reesink, Jean‐François Bergmann, Joep de Bruijne et al. · Journal of Hepatology · 2009 · 24 citations

Hepatology, Viral Hepatitis, Antiviral Drug Development +6

Human hepatic lymph nodes contain normal numbers of mature myeloid dendritic cells but few plasmacytoid dendritic cells

W Tanis, Shanta Mancham, Rekha S. Binda et al. · Clinical Immunology · 2003 · 21 citations

Autoimmune Disease, Immunology, Hematology +10

A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results

Marı́a Buti, Edward Gane, Wai‐Kay Seto et al. · Journal of Hepatology · 2016 · 17 citations

Hepatology, Viral Hepatitis, Week 48 +10

P1075 PAGE-B: RISK SCORE FOR HEPATOCELLULAR CARCINOMA (HCC) DEVELOPMENT IN CAUCASIAN CHRONIC HEPATITIS B (CHB) PATIENTS RECEIVING ENTECAVIR (ETV) OR TENOFOVIR (TDF)

George Papatheodoridis, George Ν. Dalekos, Vana Sypsa et al. · Journal of Hepatology · 2014 · 12 citations

Hepatitis B, Pathology, P1075 Page-b +18